OGENHealthcare · BiotechnologyOGEN Stock Forecast: Oragenics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 1 Aug 2026 — in the weakest quartile.
OGEN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Oragenics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (4): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Oragenics, Inc. — and when they’d sell — is the membership.
OGEN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 June 2021 | Goldman Sachs | Initiates | Neutral | — |
| 16 Apr 2020 | H.C. Wainwright | Downgrade | Neutral | — |
| 16 Apr 2020 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 15 Nov 2019 | UBS | Maintains | Neutral | — |
| 26 Apr 2019 | H.C. Wainwright | Initiates | Buy | — |
| 26 Apr 2019 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OGEN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Oragenics, Inc. (OGEN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 0.4×
- EV / EBITDA
- 0.4×
Cheaper than 73% of US stocks
Cheaper than 87% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −311.0%
- Return on assets
- −105.6%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
OGEN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OGEN appears on the weeks it earns a place.
Frequently asked questions about OGEN stock
Is OGEN stock a buy right now?
Of the 1 analysts covering Oragenics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oragenics, Inc. 19 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OGEN?
As at 1 Aug 2026, Oragenics, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
What is the OGEN stock forecast for 2030?
No analyst covering Oragenics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OGEN are extrapolating price history, which says nothing about the business.
How has OGEN stock performed over the past year?
Oragenics, Inc. returned -57.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Oragenics, Inc. do?
Oragenics Inc. is a biotechnology company that focuses on the development and commercialization of pharmaceutical products for oral health and infectious diseases.
About Oragenics, Inc.
Oragenics Inc. is a biotechnology company that focuses on the development and commercialization of pharmaceutical products for oral health and infectious diseases. The company is engaged in the creation of novel therapies utilizing its proprietary biological platform technologies. A key area of its research is aimed at the development of antibiotics to combat resistant strains of bacteria, often addressing public health challenges that require innovative solutions. Oragenics primarily targets sectors that include pharmaceuticals, healthcare, and biotherapeutics, impacting both consumer and clinical markets. The company is headquartered in Tampa, Florida, and continues to play a significant role in pioneering research within its niche, contributing to advancements in medical science and therapeutic options. By leveraging cutting-edge research in microbiomics, Oragenics is not only integral to addressing significant health concerns but also a notable contributor to the broader biotechnology and pharmaceutical industries.
CEO Ms. Janet Huffman · 3 employees · United States · https://www.oragenics.com